Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC 0 05.07.2024 12:22 Business Standard Shilpa Medicare (SML) surged 16.25% to Rs 657.30 after the company's CDMO customer, Unicycive Therapeutics, Inc. has reported positive results from pivotal clinical trial of Oxylanthanum Carbonate (OLC) to treat kidney diseases. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
